<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/>
  <meta name="type" content="article"/>
  <meta name="category" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/03/19/2020.02.25.965582.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.02.25.965582v2"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19"/>
  <meta name="DC.Identifier" content="10.1101/2020.02.25.965582"/>
  <meta name="DC.Date" content="2020-03-19"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="© 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission."/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="In 2015, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) reached the Republic of Korea through nosocomial transmission and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, only limited therapeutic options are available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactive molecules, for their activity against the isolate. The primary assay confirmed 221 hits by dose-response curve analysis and identified 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that 8 and 4 therapeutics act on the early and late stages of the viral life cycle, respectively. Among the drugs were e.g., three cardiotonic agents (ouabain, digitoxin, digoxin) with a TI greater than 100, an anti-malaria drug (atovaquone; TI &gt;;34), an inhalable corticosteroid (ciclesonide; TI &gt;;6), etc. Together, our results identify potential therapeutic options for treating MERS-CoV infections and could provide a basis for agents against a wider range of coronavirus-related illnesses, including the currently emerging Coronavirus Disease 2019 (COVID-19) outbreak. * MERS-CoV : Middle East Respiratory Syndrome Coronavirus COVID : Coronavirus Disease HCS : high-content screening DRC : dose-response curve TI : therapeutic index"/>
  <meta name="DC.Contributor" content="Meehyun Ko"/>
  <meta name="DC.Contributor" content="So Young Chang"/>
  <meta name="DC.Contributor" content="Soo Young Byun"/>
  <meta name="DC.Contributor" content="Inhee Choi"/>
  <meta name="DC.Contributor" content="Anne-Laure Pham Hung d’Alexandry d’Orengiani"/>
  <meta name="DC.Contributor" content="David Shum"/>
  <meta name="DC.Contributor" content="Ji-Young Min"/>
  <meta name="DC.Contributor" content="Marc P. Windisch"/>
  <meta name="article:published_time" content="2020-03-19"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19"/>
  <meta name="citation_abstract" lang="en" content="&lt;;p&gt;;In 2015, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) reached the Republic of Korea through nosocomial transmission and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, only limited therapeutic options are available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactive molecules, for their activity against the isolate. The primary assay confirmed 221 hits by dose-response curve analysis and identified 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that 8 and 4 therapeutics act on the early and late stages of the viral life cycle, respectively. Among the drugs were e.g., three cardiotonic agents (ouabain, digitoxin, digoxin) with a TI greater than 100, an anti-malaria drug (atovaquone; TI &amp;;gt;34), an inhalable corticosteroid (ciclesonide; TI &amp;;gt;6), etc. Together, our results identify potential therapeutic options for treating MERS-CoV infections and could provide a basis for agents against a wider range of coronavirus-related illnesses, including the currently emerging Coronavirus Disease 2019 (COVID-19) outbreak.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.02.25.965582v2"/>
  <meta name="citation_id" content="2020.02.25.965582v2"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.02.25.965582v2"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.02.25.965582v2.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.02.25.965582v2.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.02.25.965582"/>
  <meta name="citation_num_pages" content="19"/>
  <meta name="citation_article_type" content="Article"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.02.25.965582"/>
  <meta name="citation_author" content="Meehyun Ko"/>
  <meta name="citation_author_institution" content="Respiratory Virus Laboratory, Emerging Virus Group, Discovery Biology Department, Institut Pasteur Korea"/>
  <meta name="citation_author" content="So Young Chang"/>
  <meta name="citation_author_institution" content="Respiratory Virus Laboratory, Emerging Virus Group, Discovery Biology Department, Institut Pasteur Korea"/>
  <meta name="citation_author" content="Soo Young Byun"/>
  <meta name="citation_author_institution" content="Screening Discovery Platform, Translation Research Division, Institut Pasteur Korea"/>
  <meta name="citation_author" content="Inhee Choi"/>
  <meta name="citation_author_institution" content="Medicinal Chemistry, Medicinal Chemistry &amp;; Business Development Group, Translational Research Department, Institut Pasteur Korea"/>
  <meta name="citation_author" content="Anne-Laure Pham Hung d’Alexandry d’Orengiani"/>
  <meta name="citation_author_institution" content="Respiratory Virus Laboratory, Emerging Virus Group, Discovery Biology Department, Institut Pasteur Korea"/>
  <meta name="citation_author" content="David Shum"/>
  <meta name="citation_author_institution" content="Screening Discovery Platform, Translation Research Division, Institut Pasteur Korea"/>
  <meta name="citation_author" content="Ji-Young Min"/>
  <meta name="citation_author_institution" content="Respiratory Virus Laboratory, Emerging Virus Group, Discovery Biology Department, Institut Pasteur Korea"/>
  <meta name="citation_author_email" content="ji-young.x.min@gsk.com"/>
  <meta name="citation_author" content="Marc P. Windisch"/>
  <meta name="citation_author_institution" content="Applied Molecular Virology Laboratory, Unmet Medical Needs Group, Discovery Biology Department, Institut Pasteur Korea"/>
  <meta name="citation_author_institution" content="Division of Bio-Medical Science and Technology, University of Science and Technology"/>
  <meta name="citation_author_email" content="marc.windisch@ip-korea.org"/>
  <meta name="citation_reference" content="AM, Zaki, van Boheemen S, Bestebroer TM, Osterhaus AD, F.R., 2012. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. New Engl. J. Med. 367, 1814–20. https://doi.org/10.1056/NEJMoa1211721"/>
  <meta name="citation_reference" content="Bertol, J.W., Rigotto, C., De Padua, R.M., Kreis, W., Barardi, C.R.M., Braga, F.C., Simoes, C.M.O., 2011. Antiherpes activity of glucoevatromonoside, a cardenolide isolated from a Brazilian cultivar of Digitalis lanata. Antiviral Res. 92, 73–80. https://doi.org/10.1016/j.antiviral.2011.06.015"/>
  <meta name="citation_reference" content="Burkard, C., Verheije, M.H., Haagmans, B.L., van Kuppeveld, F.J., Rottier, P.J.M., Bosch, B.-J., de Haan, C.A.M., 2015. ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells. J. Virol. 89, 4434–48. https://doi.org/10.1128/JVI.03274-14"/>
  <meta name="citation_reference" content="Cho, H.-W., 2015. Outbreak of Middle East Respiratory Syndrome in Korea? Osong Public Heal. Res. Perspect. 6, 219. https://doi.org/10.1016/j.phrp.2015.08.005"/>
  <meta name="citation_reference" content="De Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., Van Nieuwkoop, S., Bestebroer, T.M., Van Den Hoogen, B.G., Neyts, J., Snijder, E.J., 2014. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875–4884. https://doi.org/10.1128/AAC.03011-14"/>
  <meta name="citation_reference" content="Dyall, J., Coleman, C.M., Hart, B.J., Venkataraman, T., Holbrook, M.R., Kindrachuk, J., Johnson, R.F., Olinger, G.G., Jahrling, P.B., Laidlaw, M., Johansen, L.M., Lear-Rooney, C.M., Glass, P.J., Hensley, L.E., Frieman, M.B., 2014. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885–4893. https://doi.org/10.1128/AAC.03036-14"/>
  <meta name="citation_reference" content="Epstein, M., 2001. Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis. 3, 398–407. https://doi.org/10.1097/00132580-200111000-00008"/>
  <meta name="citation_reference" content="Hamre, D., Procknow, J.J., 1966. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 121, 190–3."/>
  <meta name="citation_reference" content="Kapoor, A., Cai, H., Forman, M., He, R., Shamay, M., Arav-Boger, R., 2012. Human cytomegalovirus inhibition by cardiac glycosides: Evidence for involvement of the hERG gene. Antimicrob. Agents Chemother. 56, 4891–4899. https://doi.org/10.1128/AAC.00898-12"/>
  <meta name="citation_reference" content="Klein, G.R., Köppel H, 1999. Indexed in Chemical Abstracts EMBASE/Excerpta Medica Journal of Clinical and Basic Cardiology www.kup.at/jcbc Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension. J. Clin. Basic Cardiol. J Clin Basic Cardiol 2, 169–174."/>
  <meta name="citation_reference" content="Korea Centers for Disease Control and Prevention, 2015. Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015. Osong Public Heal. Res. Perspect. 6, 269–278. https://doi.org/10.1016/j.phrp.2015.08.006"/>
  <meta name="citation_reference" content="Matsuyama S., Kawase M., Nao N., Shirato K., Ujike M., Kamitani W., Shimojima M., Fukushi S. 2020. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv 2020.03.11.987016; doi: https://doi.org/10.1101/2020.03.11.987016"/>
  <meta name="citation_reference" content="McIntosh, K., Dees, J.H., Becker, W.B., Kapikian, A.Z., Chanock, R.M., 1967. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc. Natl. Acad. Sci. U. S. A. 57, 933–940. https://doi.org/10.1073/pnas.57.4.933"/>
  <meta name="citation_reference" content="Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., Almakhlafi, G.A., Albarrak, M.M., Memish, Z.A., Albarrak, A.M., 2014. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect. Dis. 14, 1090–1095. https://doi.org/10.1016/S1473-3099(14)70920-X"/>
  <meta name="citation_reference" content="Ozawa, Y., Hayashi, K., Kobori, H., 2006. New Generation Calcium Channel Blockers in Hypertensive Treatment. Curr. Hypertens. Rev. 2, 103–111. https://doi.org/10.2174/157340206776877370"/>
  <meta name="citation_reference" content="Perlman, S., Netland, J., 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7, 439–50. https://doi.org/10.1038/nrmicro2147"/>
  <meta name="citation_reference" content="Prassas, I., Diamandis, E.P., 2008. Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov. 7, 926–935. https://doi.org/10.1038/nrd2682"/>
  <meta name="citation_reference" content="Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., Mushtaq, A., 2014. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study. J. Antimicrob. Chemother. 70, 2129–2132. https://doi.org/10.1093/jac/dkv085"/>
  <meta name="citation_reference" content="Spanakis, N., Tsiodras, S., Haagmans, B.L., Raj, V.S., Pontikis, K., Koutsoukou, A., Koulouris, N.G., Osterhaus, A.D.M.E., Koopmans, M.P.G., Tsakris, A., 2014. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int. J. Antimicrob. Agents 44, 528–532. https://doi.org/10.1016/j.ijantimicag.2014.07.026"/>
  <meta name="citation_reference" content="WHO, 2019. MERS situation update, January 2019 (http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2019.html) [WWW Document]. WHO. URL http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2019.html"/>
  <meta name="citation_reference" content="WHO, 2003. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 [WWW Document]. URL http://www.who.int/csr/sars/country/table2004_04_21/en/"/>
  <meta name="citation_reference" content="World Health Organization, Novel coronavirus (2019-nCoV). https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 26 February 2020."/>
  <meta name="citation_reference" content="Wirtz, S., Herzig, S., 2004. Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine. Br. J. Pharmacol. 142, 275–284. https://doi.org/10.1038/sj.bjp.0705786"/>
  <meta name="citation_reference" content="Yang, J., Park, S., Kim, Y., Kang, H.J., Kim, H., Han, Y.W., Lee, H.S., Kim, D., Kim, A., Heo, D.R., Kim, J.A., Kim, S.J., Nam, J., Jung, H., Cheong, H., Kim, K., Lee, J., Kim, S.S., 2015. Middle East Respiratory Syndrome in 3 Persons, South Korea, 2015. Emerg. Infect. Dis. 21, 2084–2087. https://doi.org/10.3201/eid2111.151016"/>
  <meta name="citation_reference" content="Yao, K., Nagashima, K., Miki, H., 2006. Pharmacological, Pharmacokinetic, and Clinical Properties of Benidipine Hydrochloride, a Novel, Long-Acting Calcium Channel Blocker. J. Pharmacol. Sci. 100, 243–261. https://doi.org/10.1254/jphs.DTJ05001X"/>
  <meta name="citation_reference" content="Zumla, A., Chan, J.F.W., Azhar, E.I., Hui, D.S.C., Yuen, K.-Y., 2016. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15, 327–347. https://doi.org/10.1038/nrd.2015.37"/>
  <meta name="twitter:title" content="Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="In 2015, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) reached the Republic of Korea through nosocomial transmission and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, only limited therapeutic options are available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactive molecules, for their activity against the isolate. The primary assay confirmed 221 hits by dose-response curve analysis and identified 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that 8 and 4 therapeutics act on the early and late stages of the viral life cycle, respectively. Among the drugs were e.g., three cardiotonic agents (ouabain, digitoxin, digoxin) with a TI greater than 100, an anti-malaria drug (atovaquone; TI &gt;;34), an inhalable corticosteroid (ciclesonide; TI &gt;;6), etc. Together, our results identify potential therapeutic options for treating MERS-CoV infections and could provide a basis for agents against a wider range of coronavirus-related illnesses, including the currently emerging Coronavirus Disease 2019 (COVID-19) outbreak. * MERS-CoV : Middle East Respiratory Syndrome Coronavirus COVID : Coronavirus Disease HCS : high-content screening DRC : dose-response curve TI : therapeutic index"/>
  <meta name="og-title" property="og:title" content="Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.02.25.965582v2"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="In 2015, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) reached the Republic of Korea through nosocomial transmission and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, only limited therapeutic options are available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactive molecules, for their activity against the isolate. The primary assay confirmed 221 hits by dose-response curve analysis and identified 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that 8 and 4 therapeutics act on the early and late stages of the viral life cycle, respectively. Among the drugs were e.g., three cardiotonic agents (ouabain, digitoxin, digoxin) with a TI greater than 100, an anti-malaria drug (atovaquone; TI &gt;;34), an inhalable corticosteroid (ciclesonide; TI &gt;;6), etc. Together, our results identify potential therapeutic options for treating MERS-CoV infections and could provide a basis for agents against a wider range of coronavirus-related illnesses, including the currently emerging Coronavirus Disease 2019 (COVID-19) outbreak. * MERS-CoV : Middle East Respiratory Syndrome Coronavirus COVID : Coronavirus Disease HCS : high-content screening DRC : dose-response curve TI : therapeutic index"/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-03-19"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19 | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1202266 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-type-article hw-article-category-new-results"> 
  <div class="article fulltext-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2 class="">Abstract</h2>
    <p id="p-4">In 2015, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) reached the Republic of Korea through nosocomial transmission and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, only limited therapeutic options are available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactive molecules, for their activity against the isolate. The primary assay confirmed 221 hits by dose-response curve analysis and identified 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that 8 and 4 therapeutics act on the early and late stages of the viral life cycle, respectively. Among the drugs were e.g., three cardiotonic agents (ouabain, digitoxin, digoxin) with a TI greater than 100, an anti-malaria drug (atovaquone; TI &gt;;34), an inhalable corticosteroid (ciclesonide; TI &gt;;6), etc. Together, our results identify potential therapeutic options for treating MERS-CoV infections and could provide a basis for agents against a wider range of coronavirus-related illnesses, including the currently emerging Coronavirus Disease 2019 (COVID-19) outbreak.</p>
   </div>
   <div id="sec-1" class="subsection">
    <p id="p-6">Coronaviruses (CoV) are enveloped, positive-sense, single-stranded RNA viruses in the 
     <em>Coronaviridae</em> family of the 
     <em>Nidovirales</em> order. CoV usually cause mild to severe respiratory tract infections (
     <a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">Perlman and Netland, 2009</a>). Only two known types of human coronaviruses were described before 2003, coronavirus 229E and OC43, which caused mild, cold-like symptoms (
     <a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">Hamre and Procknow, 1966</a>; 
     <a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">McIntosh et al., 1967</a>). However, an outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003, which occurred mainly in Southeast Asia, was attributed to a SARS-related coronavirus. The 2003 SARS outbreak resulted in 8,096 confirmed cases and 774 deaths (fatality rate of 9.6%) (
     <a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">WHO, 2003</a>). Following the SARS epidemic, the novel coronavirus Human Coronavirus-Erasmus Medical Center (HCoV-EMC) was isolated in 2012 from a patient in Saudi Arabia who developed pneumonia and renal failure (
     <a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">AM, Zaki, van Boheemen S, Bestebroer TM, Osterhaus AD, 2012</a>). From the first outbreak in 2012 to January 2019, the HCoV-EMC epidemic resulted in 2,449 laboratory-confirmed cases and at least 845 deaths (fatality rate of 34%), mainly in the Arabian Peninsula. Thus, HCoV-EMC was renamed Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (
     <a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">WHO, 2019</a>).
    </p>
    <p id="p-7">Although most cases of MERS-CoV infection were reported in the Arabian Peninsula, another major outbreak occurred in South Korea in 2015 (
     <a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">Korea Centers for Disease Control and Prevention, 2015</a>; 
     <a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">Yang et al., 2015</a>). Notably, aside from the index case of MERS-CoV, the majority of viral transmissions in South Korea was nosocomial, with 186 confirmed cases across 16 clinics (
     <a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">Cho, 2015</a>; 
     <a id="xref-ref-11-2" class="xref-bibr" href="#ref-11">Korea Centers for Disease Control and Prevention, 2015</a>). Furthermore, continuous waves of MERS outbreaks in the Middle East have been reported by the World Health Organization (WHO), although they have been smaller than the major 2014 outbreak (
     <a id="xref-ref-20-2" class="xref-bibr" href="#ref-20">WHO, 2019</a>). Due to the severity of infection and urgent medical need for effective MERS treatment, several approaches for therapeutic development have been attempted (
     <a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">Zumla et al., 2016</a>). In clinical studies, a combination of ribavirin and interferon-alpha (IFN-α) therapy improved survival rates when administered early after the onset of infection. However, ribavirin and IFN-α treatments had no significant effect on patients in the late stage of infection (
     <a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">Omrani et al., 2014</a>; 
     <a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">Shalhoub et al., 2014</a>; 
     <a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">Spanakis et al., 2014</a>). These results suggest that broad-spectrum antiviral administration to MERS patients is effective at some points during infection, although a specific MERS-CoV treatment may be required full antiviral activity.
    </p>
    <p id="p-8">With the current pandemic of Coronavirus Disease 2019 (COVID-19), which emerged from Wuhan, China in late 2019, countries worldwide are working to control the spread of this devastating virus. The ongoing COVID-19 pandemic has already caused many human casualties and significant socio-economic losses globally. More than 219,000 confirmed COVID-19 cases and over 9,000 related fatalities worldwide have been reported (March 19, 2020). Unfortunately, CoV-specific United States Food and Drug Administration (FDA)-approved drugs are still not available in clinics.</p>
    <p id="p-9">To address urgent unmet medical needs and facilitate development of effective treatments for CoV patients, we implemented a high-content screening (HCS) strategy with the goal of repurposing newly identified MERS-CoV inhibitors for a wider range of CoV, including COVID-19. Utilizing a Korean MERS-CoV patient isolate, we screened 5,406 compounds, including FDA-approved drugs, bioactives, kinase inhibitors, and natural products. Our library included 60% of all FDA-approved drugs (1,247 out of 2,069 total) (
     <a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1A</a>). Compounds were tested for anti-MERS-CoV activity by determining the expression levels of viral spike (S) protein in infected Vero cells using immunofluorescence analysis (IFA). Two independent screens were conducted (screen 1 and screen 2) using chloroquine as a reference inhibitor at 100 μM for the maximum inhibitory concentration (IC
     <sub>90</sub> = 93 μM) (
     <a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">De Wilde et al., 2014</a>). The calculated Z’-factor of &gt;;0.78 indicated a good separation of infected cells treated with the dimethyl sulfoxide (DMSO) control and chloroquine (
     <a id="xref-fig-1-2" class="xref-fig" href="#F1">Fig. 1B</a>). Two independent HCS analyses were further conducted to select for hits demonstrating a high degree of correlation between the two replicates (R
     <sup>2</sup> = 0.91) (
     <a id="xref-fig-1-3" class="xref-fig" href="#F1">Fig. 1C</a>). Primary hits were identified by selecting compounds that demonstrated &gt;;70% MERS-CoV inhibition and &gt;;70% cell viability, thereby identifying 256 compound hits (
     <a id="xref-fig-1-4" class="xref-fig" href="#F1">Fig. 1D</a>). These hits were then confirmed using 10-point dose-response curve (DRC) analysis. From the DRC assays, IC
     <sub>50</sub> and 50% cytotoxicity concentrations (CC
     <sub>50</sub>) were determined for each compound (
     <a id="xref-fig-1-5" class="xref-fig" href="#F1">Fig. 1D</a>). A representative 10-point DRC analysis is shown in Supplementary Fig. 1. Based on the IC
     <sub>50</sub> and CC
     <sub>50</sub> analyses, we calculated therapeutic index (TI) by the ratio of CC
     <sub>50</sub>/IC
     <sub>50</sub>. From the 256 initial compound hits, 35 compounds were denoted as inactive [therapeutic index (TI ratio of CC
     <sub>50</sub>/IC
     <sub>50</sub>) values &lt;;1] and eliminated from the list of confirmed hits. Of the resulting 221 confirmed hits, 54 final compounds with an 
     <em>in vitro</em> TI &gt;;6 were selected for further testing (
     <a id="xref-fig-1-6" class="xref-fig" href="#F1">Fig. 1D</a>).
    </p>
    <div id="F1" class="fig pos-float type-figure odd">
     <div class="highwire-figure">
      <div class="fig-inline-img-wrapper">
       <div class="fig-inline-img">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F1.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Overview of small-molecule compound library composition and hit triage. (A) Our small-molecule compound library primarily comprised bioactives and FDA-approved drugs, with a small proportion of natural products and kinase inhibitors. (B) High-content screening (HCS) of 5,406 compounds in two batches in duplicate and calculation of Z[[#x2019]]-factors between high (MERS-CoV infection, black) and low (mock, green) values. (C) Correlation of duplicate screening sets. Compounds with MERS-CoV inhibition and cell viability &gt;;70% were regarded as primary hits. Scatter plot showing MERS-CoV inhibition ratios overlaid with cell viability ratios. (D) Flowchart of HCS hit selection and confirmation of final hit selection. Compounds (cpds)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1834019240" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;span xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;; class=&quot;;caption-title&quot;;&gt;;Overview of small-molecule compound library composition and hit triage.&lt;;/span&gt;; (A) Our small-molecule compound library primarily comprised bioactives and FDA-approved drugs, with a small proportion of natural products and kinase inhibitors. (B) High-content screening (HCS) of 5,406 compounds in two batches in duplicate and calculation of Z[[#x2019]]-factors between high (MERS-CoV infection, black) and low (mock, green) values. (C) Correlation of duplicate screening sets. Compounds with MERS-CoV inhibition and cell viability &gt;;70% were regarded as primary hits. Scatter plot showing MERS-CoV inhibition ratios overlaid with cell viability ratios. (D) Flowchart of HCS hit selection and confirmation of final hit selection. Compounds (cpds).&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
         <span class="hw-responsive-img">
          <img class="highwire-fragment fragment-image lazyload" alt="Fig. 1." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F1.medium.gif" width="440" height="308"/>
          <noscript>
           <img class="highwire-fragment fragment-image" alt="Fig. 1." src="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F1.medium.gif" width="440" height="308"/>
          </noscript>
         </span>
        </a>
       </div>
      </div>
      <ul class="highwire-figure-links inline">
       <li class="download-fig first">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F1.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 1." data-icon-position="" data-hide-link-title="0">Download figure</a>
       </li>
       <li class="new-tab last">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F1.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
       </li>
      </ul>
     </div>
     <div class="fig-caption">
      <span class="fig-label">Fig. 1.</span>
      <span class="caption-title">Overview of small-molecule compound library composition and hit triage.</span>
      <p id="p-10" class="first-child">(A) Our small-molecule compound library primarily comprised bioactives and FDA-approved drugs, with a small proportion of natural products and kinase inhibitors. (B) High-content screening (HCS) of 5,406 compounds in two batches in duplicate and calculation of Z’-factors between high (MERS-CoV infection, black) and low (mock, green) values. (C) Correlation of duplicate screening sets. Compounds with MERS-CoV inhibition and cell viability &gt;;70% were regarded as primary hits. Scatter plot showing MERS-CoV inhibition ratios overlaid with cell viability ratios. (D) Flowchart of HCS hit selection and confirmation of final hit selection. Compounds (cpds).</p>
      <div class="sb-div caption-clear"/>
     </div>
    </div>
    <p id="p-11">Our approach aimed to identify FDA-approved drugs and bioactives that could be promptly repurposed or developed, respectively, to treat MERS-CoV and potentially COVID-19-infected patients. In previously reported studies, small molecule libraries including approximately 300 drugs with FDA-approval or in clinical development were screened against MERS-CoV (
     <a id="xref-ref-5-2" class="xref-bibr" href="#ref-5">De Wilde et al., 2014</a>; 
     <a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">Dyall et al., 2014</a>). Here, our screening included 1,247 FDA-approved drugs, which covers approximately 60% of all FDA-approved compounds. As a result, we identified drugs not found in previous studies, indicating that opportunities for identifying novel FDA-approved drugs and bioactives by screening larger compound libraries still exist. Moreover, we corroborated four previously identified hits, including emetine dihydrochloride, ouabain, cycloheximide, and nelfinavir mesylate. These data strongly suggest that, despite the use of different viral isolates, our HCS assays and previously published screens reproducibly identified drugs that could be repurposed as potential therapeutics options for patients suffering CoV infections (
     <a id="xref-ref-6-2" class="xref-bibr" href="#ref-6">Dyall et al., 2014</a>).
    </p>
    <p id="p-12">Next, we classified the entire compound library, including the final hit compounds, into 43 categories of distinct pharmacological actions using publicly available drug databases. The results are shown in 
     <a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 2</a>, with the distribution of the entire library shown as gray bars and the final hits indicated in black. Notably, the cardiovascular agents group contained 14 compounds with TI &gt;;6 (26% of final hits). From this analysis, we found that the majority of final hits are cardiovascular agents (14 out of 54) and belong to a class of cardiac glycosides. These compounds are naturally derived agents used for treating cardiac abnormalities and modulate sodium-potassium pump action (
     <a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">Prassas and Diamandis, 2008</a>). However, glycosides have also been reported to exhibit antiviral activity against herpes simplex virus and human cytomegalovirus (
     <a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">Bertol et al., 2011</a>; 
     <a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">Kapoor et al., 2012</a>). Consistent with these previous studies, our data also indicate that the cardiac glycosides ouabain, digitoxin, and digoxin efficiently inhibit MERS-CoV infection. Specfically, ouabain has been found to block the entry stage of CoV, such as MERS-CoV, through Src kinase signaling (
     <a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">Burkard et al., 2015</a>). Based on these data, we speculate that cardiac glycosides may act as anti-MERS-CoV agents through blockage of viral entry. However, more experimental work will be required to elucidate the exact mechanism by which this occurs.
    </p>
    <div id="F2" class="fig pos-float type-figure odd">
     <div class="highwire-figure">
      <div class="fig-inline-img-wrapper">
       <div class="fig-inline-img">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F2.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Pharmacological action profiling of all library compounds and confirmed hits. The 54 final hits were sorted into 43 pharmacological action categories. Gray and black bars indicate the distribution of all screened compounds and confirmed hits with a therapeutic index (TI) &gt;;6. The vertical axis displays counts of each compound on a log scale with +1 added to the count to prevent negative values." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1834019240" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;span xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;; class=&quot;;caption-title&quot;;&gt;;Pharmacological action profiling of all library compounds and confirmed hits.&lt;;/span&gt;; The 54 final hits were sorted into 43 pharmacological action categories. Gray and black bars indicate the distribution of all screened compounds and confirmed hits with a therapeutic index (TI) &gt;;6. The vertical axis displays counts of each compound on a log scale with +1 added to the count to prevent negative values.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
         <span class="hw-responsive-img">
          <img class="highwire-fragment fragment-image lazyload" alt="Fig. 2." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F2.medium.gif" width="440" height="304"/>
          <noscript>
           <img class="highwire-fragment fragment-image" alt="Fig. 2." src="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F2.medium.gif" width="440" height="304"/>
          </noscript>
         </span>
        </a>
       </div>
      </div>
      <ul class="highwire-figure-links inline">
       <li class="download-fig first">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F2.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 2." data-icon-position="" data-hide-link-title="0">Download figure</a>
       </li>
       <li class="new-tab last">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F2.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
       </li>
      </ul>
     </div>
     <div class="fig-caption">
      <span class="fig-label">Fig. 2.</span>
      <span class="caption-title">Pharmacological action profiling of all library compounds and confirmed hits.</span>
      <p id="p-13" class="first-child">The 54 final hits were sorted into 43 pharmacological action categories. Gray and black bars indicate the distribution of all screened compounds and confirmed hits with a therapeutic index (TI) &gt;;6. The vertical axis displays counts of each compound on a log scale with +1 added to the count to prevent negative values.</p>
      <div class="sb-div caption-clear"/>
     </div>
    </div>
    <p id="p-14">Repurposing FDA-approved drugs and inhibitors with known biological functions may facilitate faster drug development due to their known pharmacological activities and safety profiles. Therefore, we prioritized 12 FDA-approved drugs and six bioactives not yet reported to have anti-CoV activities and summarized their information in 
     <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Tables 1</a> and 
     <a id="xref-table-wrap-2-1" class="xref-table" href="#T2">2</a>, respectively. An additional 26 inhibitors identified by HCS include bioactive molecules and drugs that have been in clinical trials. These inhibitors were analyzed by selecticity index (SI) based on the ratio of CC
     <sub>50</sub> to IC50 (CC
     <sub>50</sub>/IC
     <sub>50</sub>). Inhibitors with SI values between six and &gt;;156 are shown in 
     <a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Supplementary Table 1</a>.
    </p>
    <div id="T1" class="table pos-float">
     <div class="table-inline table-callout-links">
      <div class="callout">
       <span>View this table:</span>
       <ul class="callout-links">
        <li class="view-inline first">
         <a href="##" class="table-expand-inline" data-table-url="/highwire/markup/1208271/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&amp;;table-expand-inline=1" data-icon-position="" data-hide-link-title="0">View inline</a>
        </li>
        <li class="view-popup">
         <a href="/highwire/markup/1208271/expansion?width=1000&amp;;height=500&amp;;iframe=true&amp;;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">View popup</a>
        </li>
        <li class="download-ppt last">
         <a href="/highwire/powerpoint/1208271" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a>
        </li>
       </ul>
      </div>
     </div>
     <div class="table-caption">
      <span class="table-label">Table 1.</span>
      <p id="p-15" class="first-child">Hit profiling and anti-MERS-CoV efficacies of FDA-approved drugs in Vero cells
       <sup>1</sup>.
      </p>
      <div class="sb-div caption-clear"/>
     </div>
    </div>
    <div id="T2" class="table pos-float">
     <div class="table-inline table-callout-links">
      <div class="callout">
       <span>View this table:</span>
       <ul class="callout-links">
        <li class="view-inline first">
         <a href="##" class="table-expand-inline" data-table-url="/highwire/markup/1208272/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&amp;;table-expand-inline=1" data-icon-position="" data-hide-link-title="0">View inline</a>
        </li>
        <li class="view-popup">
         <a href="/highwire/markup/1208272/expansion?width=1000&amp;;height=500&amp;;iframe=true&amp;;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">View popup</a>
        </li>
        <li class="download-ppt last">
         <a href="/highwire/powerpoint/1208272" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a>
        </li>
       </ul>
      </div>
     </div>
     <div class="table-caption">
      <span class="table-label">Table 2.</span>
      <p id="p-16" class="first-child">Hit profiling and anti-MERS-CoV efficacies of selected bioactives in Vero cells
       <sup>1</sup>.
      </p>
      <div class="sb-div caption-clear"/>
     </div>
    </div>
    <p id="p-17">To investigate whether the FDA-approved drugs act on the early or late stages (pre- or post-entry) of the viral life cycle, we conducted time-of-addition studies. Vero cells were treated with each drug at a concentration higher than its IC
     <sub>90</sub> at 1 h prior to infectionor at 0, 1, 2, 3, and 4 h post-infection (hpi). Viral infection was then quantified by IFA as previously described. Infected cells treated with 0.5% DMSO were normalized to 100% infection. Chloroquine was used as an early-stage inhibitor control and inhibited MERS-CoV infection up to 30% until 3 hpi. However, chloroquine had no significant effect when administered at 4 hpi (
     <a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 3</a>). A similar effect was observed for treatment with ouabain, digitoxin, digoxin, niclosamide, regorafenib, nelfinavir mesylate, ciclesonide, and benidipine hydrochloride, which all inhibited MERS-CoV infection only when administered before 4 hpi (
     <a id="xref-fig-3-2" class="xref-fig" href="#F3">Fig. 3</a>, Supplementary Fig. 2). These data are consistent with previous reports indicating that ouabain and other cardiotonic steroids effectively block clathrin-mediated CoV endocytosis (
     <a id="xref-ref-3-2" class="xref-bibr" href="#ref-3">Burkard et al., 2015</a>; 
     <a id="xref-ref-26-2" class="xref-bibr" href="#ref-26">Zumla et al., 2016</a>). In contrast, atovaquone, lercanidipine hydrochloride, permethrin, and octocrylene had only minor inhibitory effects throughout the time-course assay, indicating that these drugs likely act on later stages of the viral life cycle (Supplementary Fig. 2). Notably, our results indicate that the dihydropyridine calcium channel blockers lercanidipine hydrochloride and benidipine hydrochloride, display different patterns of viral inhibition (
     <a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">Epstein, 2001</a>; 
     <a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">Yao et al., 2006</a>). This observation could be explained by the differing types of calcium channels that each drug affects: benidipine hydrochloride blocks triple voltage-gated calcium channels, whereas lercanidipine hydrochloride blocks single voltage-gated channels (
     <a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">Klein and Köppel H, 1999</a>; 
     <a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">Ozawa et al., 2006</a>; 
     <a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">Wirtz and Herzig, 2004</a>).
    </p>
    <div id="F3" class="fig pos-float type-figure odd">
     <div class="highwire-figure">
      <div class="fig-inline-img-wrapper">
       <div class="fig-inline-img">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F3.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Time-of-addition study with selected FDA-approved drugs. Five FDA-approved drugs were analyzed by time-course experiments to determine the stage of MERS-CoV life cycle inhibition. Vero cells were infected at a multiplicity of infection (MOI) of 5 with MERS-CoV, and FDA-approved drugs were administered at 6 time points pre- or post-infection as indicated. Drug concentrations were higher than the 90% inhibitory concentration (IC90) values of the drugs, and chloroquine was used as an early-stage control inhibitor." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1834019240" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;div xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;;&gt;;&lt;;span class=&quot;;caption-title&quot;;&gt;;Time-of-addition study with selected FDA-approved drugs.&lt;;/span&gt;; Five FDA-approved drugs were analyzed by time-course experiments to determine the stage of MERS-CoV life cycle inhibition. Vero cells were infected at a multiplicity of infection (MOI) of 5 with MERS-CoV, and FDA-approved drugs were administered at 6 time points pre- or post-infection as indicated. Drug concentrations were higher than the 90% inhibitory concentration (IC&lt;;sub&gt;;90&lt;;/sub&gt;;) values of the drugs, and chloroquine was used as an early-stage control inhibitor.&lt;;/div&gt;;&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
         <span class="hw-responsive-img">
          <img class="highwire-fragment fragment-image lazyload" alt="Fig. 3." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F3.medium.gif" width="440" height="263"/>
          <noscript>
           <img class="highwire-fragment fragment-image" alt="Fig. 3." src="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F3.medium.gif" width="440" height="263"/>
          </noscript>
         </span>
        </a>
       </div>
      </div>
      <ul class="highwire-figure-links inline">
       <li class="download-fig first">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F3.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 3." data-icon-position="" data-hide-link-title="0">Download figure</a>
       </li>
       <li class="new-tab last">
        <a href="https://www.biorxiv.org/content/biorxiv/early/2020/03/19/2020.02.25.965582/F3.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
       </li>
      </ul>
     </div>
     <div class="fig-caption">
      <span class="fig-label">Fig. 3.</span>
      <span class="caption-title">Time-of-addition study with selected FDA-approved drugs.</span>
      <p id="p-18" class="first-child">Five FDA-approved drugs were analyzed by time-course experiments to determine the stage of MERS-CoV life cycle inhibition. Vero cells were infected at a multiplicity of infection (MOI) of 5 with MERS-CoV, and FDA-approved drugs were administered at 6 time points pre- or post-infection as indicated. Drug concentrations were higher than the 90% inhibitory concentration (IC
       <sub>90</sub>) values of the drugs, and chloroquine was used as an early-stage control inhibitor.
      </p>
      <div class="sb-div caption-clear"/>
     </div>
    </div>
    <p id="p-19">In summary, we identified 12 FDA-approved drugs that could be repurposed for MERS-CoV or COVID-19 therapy. In particular, the cardiotonic drugs ouabain, digitoxin, and digoxin (TI &gt;;100 in monotherapy) are of interest that, when combined with remdesivir, a drug currently in clinical trials for treating COVID-19, or other therapeutics might yield drug synergism. Important to note, ciclesonide, used to treat asthma and allergic rhinitis by suppressing the immune system, was recently shown to inhibit MERS-CoV (
     <a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">Matsuyama et al., 2020</a>) and reported by Japanese medical doctors to have improved pneumonia symptoms in three COVID-19 patients. However, further 
     <em>in vitro</em> and 
     <em>in vivo</em> studies are required to investigate their exact antiviral mechanisms, determine potential synergistic effects, and confirm their antiviral efficacy to prioritize and select drugs for potential use in patients affected by the ongoing COVID-19 pandemic.
    </p>
   </div>
   <div class="section" id="sec-3">
    <h2 class="">Supplementary Figure Legends</h2>
    <p id="p-26">
     <strong>Supplementary Fig. 1. Example images of MERS-CoV inhibition in Vero cells. (A)</strong> The dose-response curve (DRC) for lanatoside C is a representative DRC illustrating the inhibition of MERS-CoV in Vero cells. (B) HCS was performed using an image-based assay, and compound efficacy was measured by MERS-CoV S protein inhibition. Images depict 0%, 50%, and 100% inhibition as indicated in the DRC. Scale bar = 100 μm.
    </p>
    <p id="p-27">
     <strong>Supplementary Fig. 2. Time-of-addition study with additional FDA-approved drugs.</strong> Seven FDA-approved drugs not shown in 
     <a id="xref-fig-3-3" class="xref-fig" href="#F3">Fig. 3</a> were analyzed by time-of-addition assay experiments as described in that figure.
    </p>
    <div id="T3" class="table pos-float">
     <div class="table-inline table-callout-links">
      <div class="callout">
       <span>View this table:</span>
       <ul class="callout-links">
        <li class="view-inline first">
         <a href="##" class="table-expand-inline" data-table-url="/highwire/markup/1208268/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&amp;;table-expand-inline=1" data-icon-position="" data-hide-link-title="0">View inline</a>
        </li>
        <li class="view-popup">
         <a href="/highwire/markup/1208268/expansion?width=1000&amp;;height=500&amp;;iframe=true&amp;;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">View popup</a>
        </li>
        <li class="download-ppt last">
         <a href="/highwire/powerpoint/1208268" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">Download powerpoint</a>
        </li>
       </ul>
      </div>
     </div>
     <div class="table-caption">
      <span class="table-label">Supplementary Table 1</span>
      <div class="sb-div caption-clear"/>
     </div>
    </div>
   </div>
   <div class="section ack" id="ack-1">
    <h2 class="">Acknowledgments</h2>
    <p id="p-25">This research was supported by the National Research Foundation (NRF) of Korea, which is funded by the Ministry of Science and ICT [2016M3A9B6918984, 2017M3A9G6068245].</p>
   </div>
   <div class="section fn-group" id="fn-group-1">
    <h2>Footnotes</h2>
    <ul>
     <li class="fn-update fn-group-summary-of-updates" id="fn-3">
      <p id="p-5">The manuscript has been updated with new information on potential therapies for COVID-19.</p>
     </li>
    </ul>
   </div>
   <div class="section glossary">
    <h2 class="">Abbreviations</h2>
    <dl id="def-list-1">
     <dt id="def-item-1">MERS-CoV
      <span class="def-item-dt-sep"/>
     </dt>
     <dd>Middle East Respiratory Syndrome Coronavirus
      <span class="def-item-dd-sep"/>
     </dd>
     <dt id="def-item-2">COVID
      <span class="def-item-dt-sep"/>
     </dt>
     <dd>Coronavirus Disease
      <span class="def-item-dd-sep"/>
     </dd>
     <dt id="def-item-3">HCS
      <span class="def-item-dt-sep"/>
     </dt>
     <dd>high-content screening
      <span class="def-item-dd-sep"/>
     </dd>
     <dt id="def-item-4">DRC
      <span class="def-item-dt-sep"/>
     </dt>
     <dd>dose-response curve
      <span class="def-item-dd-sep"/>
     </dd>
     <dt id="def-item-5">TI
      <span class="def-item-dt-sep"/>
     </dt>
     <dd>therapeutic index</dd>
    </dl>
   </div>
   <div class="section ref-list" id="ref-list-1">
    <h2 class="">References</h2>
    <ol class="cit-list ref-use-labels">
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference in text" id="ref-1">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.1" data-doi="10.1056/NEJMoa1211721">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-given-names">AM</span>, 
          <span class="cit-name-surname">Zaki</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">van Boheemen</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bestebroer</span>
          <span class="cit-name-given-names">TM</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Osterhaus</span>
          <span class="cit-name-given-names">AD</span>
         </span>, F.R., 
         <span class="cit-pub-date">2012</span>. 
         <span class="cit-article-title">Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia</span>. 
         <abbr class="cit-jnl-abbrev">New Engl. J. Med.</abbr>
         <span class="cit-vol">367</span>, 
         <span class="cit-fpage">1814</span>–
         <span class="cit-lpage">20</span>. 
         <a href="https://doi.org/10.1056/NEJMoa1211721">https://doi.org/10.1056/NEJMoa1211721</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.stitle%253DNEJM%26rft.aulast%253DZaki%26rft.auinit1%253DA.%2BM.%26rft.volume%253D367%26rft.issue%253D19%26rft.spage%253D1814%26rft.epage%253D1820%26rft.atitle%253DIsolation%2Bof%2Ba%2Bnovel%2Bcoronavirus%2Bfrom%2Ba%2Bman%2Bwith%2Bpneumonia%2Bin%2BSaudi%2BArabia.%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa1211721%26rft_id%253Dinfo%253Apmid%252F23075143%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1056/NEJMoa1211721&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=23075143&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000310773200008&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference in text" id="ref-2">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.2">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Bertol</span>, 
          <span class="cit-name-given-names">J.W.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Rigotto</span>, 
          <span class="cit-name-given-names">C.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">De Padua</span>, 
          <span class="cit-name-given-names">R.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kreis</span>, 
          <span class="cit-name-given-names">W.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Barardi</span>, 
          <span class="cit-name-given-names">C.R.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Braga</span>, 
          <span class="cit-name-given-names">F.C.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Simoes</span>, 
          <span class="cit-name-given-names">C.M.O.</span>
         </span>, 
         <span class="cit-pub-date">2011</span>. 
         <span class="cit-article-title">Antiherpes activity of glucoevatromonoside, a cardenolide isolated from a Brazilian cultivar of Digitalis lanata</span>. 
         <abbr class="cit-jnl-abbrev">Antiviral Res.</abbr>
         <span class="cit-vol">92</span>, 
         <span class="cit-fpage">73</span>–
         <span class="cit-lpage">80</span>. 
         <a href="https://doi.org/10.1016/j.antiviral.2011.06.015">https://doi.org/10.1016/j.antiviral.2011.06.015</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntiviral%2Bresearch%26rft.stitle%253DAntiviral%2BRes%26rft.aulast%253DBertol%26rft.auinit1%253DJ.%2BW.%26rft.volume%253D92%26rft.issue%253D1%26rft.spage%253D73%26rft.epage%253D80%26rft.atitle%253DAntiherpes%2Bactivity%2Bof%2Bglucoevatromonoside%252C%2Ba%2Bcardenolide%2Bisolated%2Bfrom%2Ba%2BBrazilian%2Bcultivar%2Bof%2BDigitalis%2Blanata.%26rft_id%253Dinfo%253Apmid%252F21763352%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=21763352&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference in text" id="ref-3">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.3" data-doi="10.1128/JVI.03274-14">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Burkard</span>, 
          <span class="cit-name-given-names">C.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Verheije</span>, 
          <span class="cit-name-given-names">M.H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Haagmans</span>, 
          <span class="cit-name-given-names">B.L.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">van Kuppeveld</span>, 
          <span class="cit-name-given-names">F.J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Rottier</span>, 
          <span class="cit-name-given-names">P.J.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bosch</span>, 
          <span class="cit-name-given-names">B.-J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">de Haan</span>, 
          <span class="cit-name-given-names">C.A.M.</span>
         </span>, 
         <span class="cit-pub-date">2015</span>. 
         <span class="cit-article-title">ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells</span>. 
         <abbr class="cit-jnl-abbrev">J. Virol.</abbr>
         <span class="cit-vol">89</span>, 
         <span class="cit-fpage">4434</span>–
         <span class="cit-lpage">48</span>. 
         <a href="https://doi.org/10.1128/JVI.03274-14">https://doi.org/10.1128/JVI.03274-14</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJ.%2BVirol.%26rft_id%253Dinfo%253Adoi%252F10.1128%252FJVI.03274-14%26rft_id%253Dinfo%253Apmid%252F25653449%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoianZpIjtzOjU6InJlc2lkIjtzOjk6Ijg5LzgvNDQzNCI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzAzLzE5LzIwMjAuMDIuMjUuOTY1NTgyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference in text" id="ref-4">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.4">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Cho</span>, 
          <span class="cit-name-given-names">H.-W.</span>
         </span>, 
         <span class="cit-pub-date">2015</span>. 
         <span class="cit-article-title">Outbreak of Middle East Respiratory Syndrome in Korea?</span>
         <abbr class="cit-jnl-abbrev">Osong Public Heal. Res. Perspect.</abbr>
         <span class="cit-vol">6</span>, 
         <span class="cit-fpage">219</span>. 
         <a href="https://doi.org/10.1016/j.phrp.2015.08.005">https://doi.org/10.1016/j.phrp.2015.08.005</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DOsong%2BPublic%2BHeal.%2BRes.%2BPerspect.%26rft.volume%253D6%26rft.spage%253D219%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference in text" id="ref-5">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.5" data-doi="10.1128/AAC.03011-14">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">De Wilde</span>, 
          <span class="cit-name-given-names">A.H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Jochmans</span>, 
          <span class="cit-name-given-names">D.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Posthuma</span>, 
          <span class="cit-name-given-names">C.C.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zevenhoven-Dobbe</span>, 
          <span class="cit-name-given-names">J.C.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Van Nieuwkoop</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bestebroer</span>, 
          <span class="cit-name-given-names">T.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Van Den Hoogen</span>, 
          <span class="cit-name-given-names">B.G.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Neyts</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Snijder</span>, 
          <span class="cit-name-given-names">E.J.</span>
         </span>, 
         <span class="cit-pub-date">2014</span>. 
         <span class="cit-article-title">Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</span>. 
         <abbr class="cit-jnl-abbrev">Antimicrob. Agents Chemother.</abbr>
         <span class="cit-vol">58</span>, 
         <span class="cit-fpage">4875</span>–
         <span class="cit-lpage">4884</span>. 
         <a href="https://doi.org/10.1128/AAC.03011-14">https://doi.org/10.1128/AAC.03011-14</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntimicrob.%2BAgents%2BChemother.%26rft_id%253Dinfo%253Adoi%252F10.1128%252FAAC.03011-14%26rft_id%253Dinfo%253Apmid%252F24841269%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYWFjIjtzOjU6InJlc2lkIjtzOjk6IjU4LzgvNDg3NSI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzAzLzE5LzIwMjAuMDIuMjUuOTY1NTgyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference in text" id="ref-6">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.6" data-doi="10.1128/AAC.03036-14">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Dyall</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Coleman</span>, 
          <span class="cit-name-given-names">C.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Hart</span>, 
          <span class="cit-name-given-names">B.J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Venkataraman</span>, 
          <span class="cit-name-given-names">T.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Holbrook</span>, 
          <span class="cit-name-given-names">M.R.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kindrachuk</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Johnson</span>, 
          <span class="cit-name-given-names">R.F.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Olinger</span>, 
          <span class="cit-name-given-names">G.G.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Jahrling</span>, 
          <span class="cit-name-given-names">P.B.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Laidlaw</span>, 
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Johansen</span>, 
          <span class="cit-name-given-names">L.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Lear-Rooney</span>, 
          <span class="cit-name-given-names">C.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Glass</span>, 
          <span class="cit-name-given-names">P.J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Hensley</span>, 
          <span class="cit-name-given-names">L.E.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Frieman</span>, 
          <span class="cit-name-given-names">M.B.</span>
         </span>, 
         <span class="cit-pub-date">2014</span>. 
         <span class="cit-article-title">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span>. 
         <abbr class="cit-jnl-abbrev">Antimicrob. Agents Chemother.</abbr>
         <span class="cit-vol">58</span>, 
         <span class="cit-fpage">4885</span>–
         <span class="cit-lpage">4893</span>. 
         <a href="https://doi.org/10.1128/AAC.03036-14">https://doi.org/10.1128/AAC.03036-14</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntimicrob.%2BAgents%2BChemother.%26rft_id%253Dinfo%253Adoi%252F10.1128%252FAAC.03036-14%26rft_id%253Dinfo%253Apmid%252F24841273%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYWFjIjtzOjU6InJlc2lkIjtzOjk6IjU4LzgvNDg4NSI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzAzLzE5LzIwMjAuMDIuMjUuOTY1NTgyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference in text" id="ref-7">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.7">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Epstein</span>, 
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-pub-date">2001</span>. 
         <span class="cit-article-title">Lercanidipine: a novel dihydropyridine calcium-channel blocker</span>. 
         <abbr class="cit-jnl-abbrev">Heart Dis.</abbr>
         <span class="cit-vol">3</span>, 
         <span class="cit-fpage">398</span>–
         <span class="cit-lpage">407</span>. 
         <a href="https://doi.org/10.1097/00132580-200111000-00008">https://doi.org/10.1097/00132580-200111000-00008</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DHeart%2Bdisease%2B%2528Hagerstown%252C%2BMd.%2529%26rft.stitle%253DHeart%2BDis%26rft.aulast%253DEpstein%26rft.auinit1%253DM.%26rft.volume%253D3%26rft.issue%253D6%26rft.spage%253D398%26rft.epage%253D407%26rft.atitle%253DLercanidipine%253A%2Ba%2Bnovel%2Bdihydropyridine%2Bcalcium-channel%2Bblocker.%26rft_id%253Dinfo%253Apmid%252F11975824%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=11975824&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference in text" id="ref-8">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.8" data-doi="10.3181/00379727-121-30734">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Hamre</span>, 
          <span class="cit-name-given-names">D.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Procknow</span>, 
          <span class="cit-name-given-names">J.J.</span>
         </span>, 
         <span class="cit-pub-date">1966</span>. 
         <span class="cit-article-title">A new virus isolated from the human respiratory tract</span>. 
         <abbr class="cit-jnl-abbrev">Proc. Soc. Exp. Biol. Med.</abbr>
         <span class="cit-vol">121</span>, 
         <span class="cit-fpage">190</span>–
         <span class="cit-lpage">3</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DExperimental%2BBiology%2Band%2BMedicine%26rft.stitle%253DExp%2BBiol%2BMed%2B%2528Maywood%2529%26rft.aulast%253DHamre%26rft.auinit1%253DD.%26rft.volume%253D121%26rft.issue%253D1%26rft.spage%253D190%26rft.epage%253D193%26rft.atitle%253DA%2BNew%2BVirus%2BIsolated%2Bfrom%2Bthe%2BHuman%2BRespiratory%2BTract.%26rft_id%253Dinfo%253Adoi%252F10.3181%252F00379727-121-30734%26rft_id%253Dinfo%253Apmid%252F4285768%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.3181/00379727-121-30734&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=4285768&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference in text" id="ref-9">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.9" data-doi="10.1128/AAC.00898-12">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Kapoor</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Cai</span>, 
          <span class="cit-name-given-names">H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Forman</span>, 
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">He</span>, 
          <span class="cit-name-given-names">R.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shamay</span>, 
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Arav-Boger</span>, 
          <span class="cit-name-given-names">R.</span>
         </span>, 
         <span class="cit-pub-date">2012</span>. 
         <span class="cit-article-title">Human cytomegalovirus inhibition by cardiac glycosides: Evidence for involvement of the hERG gene</span>. 
         <abbr class="cit-jnl-abbrev">Antimicrob. Agents Chemother.</abbr>
         <span class="cit-vol">56</span>, 
         <span class="cit-fpage">4891</span>–
         <span class="cit-lpage">4899</span>. 
         <a href="https://doi.org/10.1128/AAC.00898-12">https://doi.org/10.1128/AAC.00898-12</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntimicrob.%2BAgents%2BChemother.%26rft_id%253Dinfo%253Adoi%252F10.1128%252FAAC.00898-12%26rft_id%253Dinfo%253Apmid%252F22777050%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYWFjIjtzOjU6InJlc2lkIjtzOjk6IjU2LzkvNDg5MSI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzAzLzE5LzIwMjAuMDIuMjUuOTY1NTgyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference in text" id="ref-10">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.10">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Klein</span>, 
          <span class="cit-name-given-names">G.R.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Köppel</span>
          <span class="cit-name-given-names">H</span>
         </span>, 
         <span class="cit-pub-date">1999</span>. 
         <span class="cit-article-title">Indexed in Chemical Abstracts EMBASE/Excerpta Medica Journal of Clinical and Basic Cardiology 
          <a href="http://www.kup.at/jcbc">www.kup.at/jcbc</a> Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension
         </span>. 
         <abbr class="cit-jnl-abbrev">J. Clin. Basic Cardiol. J Clin Basic Cardiol</abbr>
         <span class="cit-vol">2</span>, 
         <span class="cit-fpage">169</span>–
         <span class="cit-lpage">174</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJ.%2BClin.%2BBasic%2BCardiol.%2BJ%2BClin%2BBasic%2BCardiol%26rft.volume%253D2%26rft.spage%253D169%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference in text" id="ref-11">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.11">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth cit-collab">Korea Centers for Disease Control and Prevention</span>, 
         <span class="cit-pub-date">2015</span>. 
         <span class="cit-article-title">Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015</span>. 
         <abbr class="cit-jnl-abbrev">Osong Public Heal. Res. Perspect.</abbr>
         <span class="cit-vol">6</span>, 
         <span class="cit-fpage">269</span>–
         <span class="cit-lpage">278</span>. 
         <a href="https://doi.org/10.1016/j.phrp.2015.08.006">https://doi.org/10.1016/j.phrp.2015.08.006</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DOsong%2BPublic%2BHeal.%2BRes.%2BPerspect.%26rft.volume%253D6%26rft.spage%253D269%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference in text" id="ref-12">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.12">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Matsuyama</span>
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kawase</span>
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Nao</span>
          <span class="cit-name-given-names">N.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shirato</span>
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Ujike</span>
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kamitani</span>
          <span class="cit-name-given-names">W.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shimojima</span>
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Fukushi</span>
          <span class="cit-name-given-names">S</span>
         </span>. 
         <span class="cit-pub-date">2020</span>. 
         <span class="cit-article-title">The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15</span>. 
         <abbr class="cit-jnl-abbrev">bioRxiv</abbr>
         <span class="cit-fpage">2020.03.11.987016</span>; doi: 
         <a href="https://doi.org/10.1101/2020.03.11.987016">https://doi.org/10.1101/2020.03.11.987016</a>
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference in text" id="ref-13">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.13" data-doi="10.1073/pnas.57.4.933">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">McIntosh</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Dees</span>, 
          <span class="cit-name-given-names">J.H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Becker</span>, 
          <span class="cit-name-given-names">W.B.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kapikian</span>, 
          <span class="cit-name-given-names">A.Z.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Chanock</span>, 
          <span class="cit-name-given-names">R.M.</span>
         </span>, 
         <span class="cit-pub-date">1967</span>. 
         <span class="cit-article-title">Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease</span>. 
         <abbr class="cit-jnl-abbrev">Proc. Natl. Acad. Sci. U. S. A.</abbr>
         <span class="cit-vol">57</span>, 
         <span class="cit-fpage">933</span>–
         <span class="cit-lpage">940</span>. 
         <a href="https://doi.org/10.1073/pnas.57.4.933">https://doi.org/10.1073/pnas.57.4.933</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DPNAS%26rft.stitle%253DProc.%2BNatl.%2BAcad.%2BSci.%2BUSA%26rft.aulast%253DMcIntosh%26rft.auinit1%253DK.%26rft.volume%253D57%26rft.issue%253D4%26rft.spage%253D933%26rft.epage%253D940%26rft.atitle%253DRecovery%2Bin%2Btracheal%2Borgan%2Bcultures%2Bof%2Bnovel%2Bviruses%2Bfrom%2Bpatients%2Bwith%2Brespiratory%2Bdisease.%26rft_id%253Dinfo%253Adoi%252F10.1073%252Fpnas.57.4.933%26rft_id%253Dinfo%253Apmid%252F5231356%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czo4OiI1Ny80LzkzMyI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzAzLzE5LzIwMjAuMDIuMjUuOTY1NTgyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference in text" id="ref-14">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.14" data-doi="10.1016/S1473-3099(14)70920-X">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Omrani</span>, 
          <span class="cit-name-given-names">A.S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Saad</span>, 
          <span class="cit-name-given-names">M.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Baig</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bahloul</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Abdul-Matin</span>, 
          <span class="cit-name-given-names">M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Alaidaroos</span>, 
          <span class="cit-name-given-names">A.Y.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Almakhlafi</span>, 
          <span class="cit-name-given-names">G.A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Albarrak</span>, 
          <span class="cit-name-given-names">M.M.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Memish</span>, 
          <span class="cit-name-given-names">Z.A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Albarrak</span>, 
          <span class="cit-name-given-names">A.M.</span>
         </span>, 
         <span class="cit-pub-date">2014</span>. 
         <span class="cit-article-title">Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study</span>. 
         <abbr class="cit-jnl-abbrev">Lancet Infect. Dis.</abbr>
         <span class="cit-vol">14</span>, 
         <span class="cit-fpage">1090</span>–
         <span class="cit-lpage">1095</span>. 
         <a href="https://doi.org/10.1016/S1473-3099(14)70920-X">https://doi.org/10.1016/S1473-3099(14)70920-X</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DLancet%2BInfect.%2BDis.%26rft.volume%253D14%26rft.spage%253D1090%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1473-3099%252814%252970920-X%26rft_id%253Dinfo%253Apmid%252F25278221%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/S1473-3099(14)70920-X&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=25278221&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000343743700034&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference in text" id="ref-15">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.15">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Ozawa</span>, 
          <span class="cit-name-given-names">Y.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Hayashi</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kobori</span>, 
          <span class="cit-name-given-names">H.</span>
         </span>, 
         <span class="cit-pub-date">2006</span>. 
         <span class="cit-article-title">New Generation Calcium Channel Blockers in Hypertensive Treatment</span>. 
         <abbr class="cit-jnl-abbrev">Curr. Hypertens. Rev.</abbr>
         <span class="cit-vol">2</span>, 
         <span class="cit-fpage">103</span>–
         <span class="cit-lpage">111</span>. 
         <a href="https://doi.org/10.2174/157340206776877370">https://doi.org/10.2174/157340206776877370</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.stitle%253DCurr%2BHypertens%2BRev%26rft.aulast%253DOzawa%26rft.auinit1%253DY.%26rft.volume%253D2%26rft.issue%253D2%26rft.spage%253D103%26rft.epage%253D111%26rft.atitle%253DNew%2BGeneration%2BCalcium%2BChannel%2BBlockers%2Bin%2BHypertensive%2BTreatment.%26rft_id%253Dinfo%253Apmid%252F19823601%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=19823601&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference in text" id="ref-16">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.16" data-doi="10.1038/nrmicro2147">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Perlman</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Netland</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-pub-date">2009</span>. 
         <span class="cit-article-title">Coronaviruses post-SARS: update on replication and pathogenesis</span>. 
         <abbr class="cit-jnl-abbrev">Nat. Rev. Microbiol.</abbr>
         <span class="cit-vol">7</span>, 
         <span class="cit-fpage">439</span>–
         <span class="cit-lpage">50</span>. 
         <a href="https://doi.org/10.1038/nrmicro2147">https://doi.org/10.1038/nrmicro2147</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNature%2Breviews.%2BMicrobiology%26rft.stitle%253DNat%2BRev%2BMicrobiol%26rft.aulast%253DPerlman%26rft.auinit1%253DS.%26rft.volume%253D7%26rft.issue%253D6%26rft.spage%253D439%26rft.epage%253D450%26rft.atitle%253DCoronaviruses%2Bpost-SARS%253A%2Bupdate%2Bon%2Breplication%2Band%2Bpathogenesis.%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnrmicro2147%26rft_id%253Dinfo%253Apmid%252F19430490%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/nrmicro2147&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=19430490&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference in text" id="ref-17">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.17" data-doi="10.1038/nrd2682">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Prassas</span>, 
          <span class="cit-name-given-names">I.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Diamandis</span>, 
          <span class="cit-name-given-names">E.P.</span>
         </span>, 
         <span class="cit-pub-date">2008</span>. 
         <span class="cit-article-title">Novel therapeutic applications of cardiac glycosides</span>. 
         <abbr class="cit-jnl-abbrev">Nat. Rev. Drug Discov.</abbr>
         <span class="cit-vol">7</span>, 
         <span class="cit-fpage">926</span>–
         <span class="cit-lpage">935</span>. 
         <a href="https://doi.org/10.1038/nrd2682">https://doi.org/10.1038/nrd2682</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNature%2Breviews.%2BDrug%2Bdiscovery%26rft.stitle%253DNat%2BRev%2BDrug%2BDiscov%26rft.aulast%253DPrassas%26rft.auinit1%253DI.%26rft.volume%253D7%26rft.issue%253D11%26rft.spage%253D926%26rft.epage%253D935%26rft.atitle%253DNovel%2Btherapeutic%2Bapplications%2Bof%2Bcardiac%2Bglycosides.%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnrd2682%26rft_id%253Dinfo%253Apmid%252F18948999%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/nrd2682&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=18948999&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000260532400023&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference in text" id="ref-18">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.18">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Shalhoub</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Farahat</span>, 
          <span class="cit-name-given-names">F.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Al-Jiffri</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Simhairi</span>, 
          <span class="cit-name-given-names">R.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shamma</span>, 
          <span class="cit-name-given-names">O.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Siddiqi</span>, 
          <span class="cit-name-given-names">N.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Mushtaq</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-pub-date">2014</span>. 
         <span class="cit-article-title">IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study</span>. 
         <abbr class="cit-jnl-abbrev">J. Antimicrob. Chemother.</abbr>
         <span class="cit-vol">70</span>, 
         <span class="cit-fpage">2129</span>–
         <span class="cit-lpage">2132</span>. 
         <a href="https://doi.org/10.1093/jac/dkv085">https://doi.org/10.1093/jac/dkv085</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJ.%2BAntimicrob.%2BChemother.%26rft.volume%253D70%26rft.spage%253D2129%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference in text" id="ref-19">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.19" data-doi="10.1016/j.ijantimicag.2014.07.026">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Spanakis</span>, 
          <span class="cit-name-given-names">N.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Tsiodras</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Haagmans</span>, 
          <span class="cit-name-given-names">B.L.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Raj</span>, 
          <span class="cit-name-given-names">V.S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Pontikis</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Koutsoukou</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Koulouris</span>, 
          <span class="cit-name-given-names">N.G.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Osterhaus</span>, 
          <span class="cit-name-given-names">A.D.M.E.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Koopmans</span>, 
          <span class="cit-name-given-names">M.P.G.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Tsakris</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-pub-date">2014</span>. 
         <span class="cit-article-title">Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen</span>. 
         <abbr class="cit-jnl-abbrev">Int. J. Antimicrob. Agents</abbr>
         <span class="cit-vol">44</span>, 
         <span class="cit-fpage">528</span>–
         <span class="cit-lpage">532</span>. 
         <a href="https://doi.org/10.1016/j.ijantimicag.2014.07.026">https://doi.org/10.1016/j.ijantimicag.2014.07.026</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DInt.%2BJ.%2BAntimicrob.%2BAgents%26rft.volume%253D44%26rft.spage%253D528%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ijantimicag.2014.07.026%26rft_id%253Dinfo%253Apmid%252F25288266%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/j.ijantimicag.2014.07.026&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=25288266&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference in text" id="ref-20">↵</a>
      <div class="cit ref-cit ref-web" id="cit-2020.02.25.965582v2.20">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth cit-collab">WHO</span>, 
         <span class="cit-pub-date">2019</span>. 
         <span class="cit-article-title">MERS situation update</span>, 
         <span class="cit-month">January</span> 2019 (
         <a href="http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2019.html">http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2019.html</a>) [WWW Document]. WHO. URL 
         <a href="http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2019.html">http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2019.html</a>
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference in text" id="ref-21">↵</a>
      <div class="cit ref-cit ref-web" id="cit-2020.02.25.965582v2.21">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth cit-collab">WHO</span>, 
         <span class="cit-pub-date">2003</span>. 
         <span class="cit-article-title">Summary of probable SARS cases with onset of illness</span> from 1 November 2002 to 31 July 2003 [WWW Document]. URL 
         <a href="http://www.who.int/csr/sars/country/table2004_04_21/en/">http://www.who.int/csr/sars/country/table2004_04_21/en/</a>
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <div class="cit ref-cit ref-web no-rev-xref" id="cit-2020.02.25.965582v2.22">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth cit-collab">World Health Organization</span>, 
         <span class="cit-article-title">Novel coronavirus (2019-nCoV)</span>. 
         <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</a>. Accessed 
         <span class="cit-date-in-citation">26 February 2020</span>.
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference in text" id="ref-23">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.23">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Wirtz</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Herzig</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-pub-date">2004</span>. 
         <span class="cit-article-title">Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine</span>. 
         <abbr class="cit-jnl-abbrev">Br. J. Pharmacol.</abbr>
         <span class="cit-vol">142</span>, 
         <span class="cit-fpage">275</span>–
         <span class="cit-lpage">284</span>. 
         <a href="https://doi.org/10.1038/sj.bjp.0705786">https://doi.org/10.1038/sj.bjp.0705786</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DBritish%2Bjournal%2Bof%2Bpharmacology%26rft.stitle%253DBr%2BJ%2BPharmacol%26rft.aulast%253DWirtz%26rft.auinit1%253DS.%26rft.volume%253D142%26rft.issue%253D2%26rft.spage%253D275%26rft.epage%253D284%26rft.atitle%253DMolecular%2Bmechanisms%2Bof%2Bvasoselectivity%2Bof%2Bthe%2B1%252C4-dihydropyridine%2Blercanidipine.%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference in text" id="ref-24">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.24" data-doi="10.3201/eid2111.151016">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Yang</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Park</span>, 
          <span class="cit-name-given-names">S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>, 
          <span class="cit-name-given-names">Y.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kang</span>, 
          <span class="cit-name-given-names">H.J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>, 
          <span class="cit-name-given-names">H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Han</span>, 
          <span class="cit-name-given-names">Y.W.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Lee</span>, 
          <span class="cit-name-given-names">H.S.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>, 
          <span class="cit-name-given-names">D.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Heo</span>, 
          <span class="cit-name-given-names">D.R.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>, 
          <span class="cit-name-given-names">J.A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>, 
          <span class="cit-name-given-names">S.J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Nam</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Jung</span>, 
          <span class="cit-name-given-names">H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Cheong</span>, 
          <span class="cit-name-given-names">H.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Lee</span>, 
          <span class="cit-name-given-names">J.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>, 
          <span class="cit-name-given-names">S.S.</span>
         </span>, 
         <span class="cit-pub-date">2015</span>. 
         <span class="cit-article-title">Middle East Respiratory Syndrome in 3 Persons, South Korea, 2015</span>. 
         <abbr class="cit-jnl-abbrev">Emerg. Infect. Dis.</abbr>
         <span class="cit-vol">21</span>, 
         <span class="cit-fpage">2084</span>–
         <span class="cit-lpage">2087</span>. 
         <a href="https://doi.org/10.3201/eid2111.151016">https://doi.org/10.3201/eid2111.151016</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DEmerg.%2BInfect.%2BDis.%26rft.volume%253D21%26rft.spage%253D2084%26rft_id%253Dinfo%253Adoi%252F10.3201%252Feid2111.151016%26rft_id%253Dinfo%253Apmid%252F26488745%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.3201/eid2111.151016&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=26488745&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference in text" id="ref-25">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.25" data-doi="10.1254/jphs.DTJ05001X">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Yao</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Nagashima</span>, 
          <span class="cit-name-given-names">K.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Miki</span>, 
          <span class="cit-name-given-names">H.</span>
         </span>, 
         <span class="cit-pub-date">2006</span>. 
         <span class="cit-article-title">Pharmacological, Pharmacokinetic, and Clinical Properties of Benidipine Hydrochloride, a Novel, Long-Acting Calcium Channel Blocker</span>. 
         <abbr class="cit-jnl-abbrev">J. Pharmacol. Sci.</abbr>
         <span class="cit-vol">100</span>, 
         <span class="cit-fpage">243</span>–
         <span class="cit-lpage">261</span>. 
         <a href="https://doi.org/10.1254/jphs.DTJ05001X">https://doi.org/10.1254/jphs.DTJ05001X</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJ.%2BPharmacol.%2BSci.%26rft.volume%253D100%26rft.spage%253D243%26rft_id%253Dinfo%253Adoi%252F10.1254%252Fjphs.DTJ05001X%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1254/jphs.DTJ05001X&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference in text" id="ref-26">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.02.25.965582v2.26" data-doi="10.1038/nrd.2015.37">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Zumla</span>, 
          <span class="cit-name-given-names">A.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Chan</span>, 
          <span class="cit-name-given-names">J.F.W.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Azhar</span>, 
          <span class="cit-name-given-names">E.I.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Hui</span>, 
          <span class="cit-name-given-names">D.S.C.</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Yuen</span>, 
          <span class="cit-name-given-names">K.-Y.</span>
         </span>, 
         <span class="cit-pub-date">2016</span>. 
         <span class="cit-article-title">Coronaviruses - drug discovery and therapeutic options</span>. 
         <abbr class="cit-jnl-abbrev">Nat. Rev. Drug Discov.</abbr>
         <span class="cit-vol">15</span>, 
         <span class="cit-fpage">327</span>–
         <span class="cit-lpage">347</span>. 
         <a href="https://doi.org/10.1038/nrd.2015.37">https://doi.org/10.1038/nrd.2015.37</a>
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNat.%2BRev.%2BDrug%2BDiscov.%26rft.volume%253D15%26rft.spage%253D327%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnrd.2015.37%26rft_id%253Dinfo%253Apmid%252F26868298%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/nrd.2015.37&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=26868298&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F03%2F19%2F2020.02.25.965582.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
    </ol>
   </div>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
